Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.20 0.85% 1,439.60 1,440.80 1,441.20 1,451.60 1,416.40 1,421.80 9,432,627 16:35:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.0 5,442.0 87.6 16.4 58,554

GlaxoSmithKline Capital PLC Publication of Supplementary EMTN Prospectus

23/11/2022 7:44am

UK Regulatory (RNS & others)

Historical Stock Chart

From Nov 2022 to Feb 2023

Click Here for more Gsk Charts.


RNS Number : 2515H

GlaxoSmithKline Capital PLC

22 November 2022

Issued: 22 November 2022, London UK - LSE Announcement

GlaxoSmithKline Capital plc Publication of Supplement to the Base Prospectus

GlaxoSmithKline Capital plc today announced that the following supplement dated 22 November 2022 to the base prospectus dated 7 September 2022 (as supplemented by the prospectus supplement dated 3 November 2022 and by the prospectus supplement dated 18 November 2022) has been approved by the UK Listing Authority and is available for viewing:

GSK plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K. GBP20,000,000,000 Euro Medium Term Note Programme

Copies of the supplement to the base prospectus and the documents incorporated by reference within it have been submitted to the National Storage Mechanism and will shortly be available for inspection at and can be downloaded from:

For further information, please contact:

GSK plc

980 Great West Road




United Kingdom


 UK Media enquiries:         Tim Foley        +44 (0) 20 8047 
 European Analyst/Investor   Nick Stone       +44 (0) 7717 618 
  enquiries:                                   834 
                              James Dodwell 
                                               +44 (0) 7881 269 


Please note that the information contained in the supplement to the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the supplement to the base prospectus is not addressed. Prior to relying on the information contained in the supplement to the base prospectus you must ascertain from the supplement to the base p rospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at

 GSK plc 
  Registered in England & Wales: 
  No. 3888792 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

November 22, 2022 11:00 ET (16:00 GMT)

1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20230203 23:46:05